瑞拉可利安联合白蛋白结合型紫杉醇治疗复发性铂耐药卵巢癌:三臂随机对照开放标签II期研究
这项三臂随机对照开放标签II期研究纳入178例复发性铂耐药/难治性高级别浆液性或子宫内膜样卵巢癌等患者,比较间歇瑞拉可利安联合白蛋白结合型紫杉醇、持续瑞拉可利安联合白蛋白结合型紫杉醇与白蛋白结合型紫杉醇单药。间歇组较单药组改善无进展生存期(HR 0.66,P=.038)和缓解持续时间(HR 0.36,P=.006),但按方案预设Hochberg逐步多重性校正,主要终点未达统计学显著(P<.025)。
要点
- 间歇瑞拉可利安联合白蛋白结合型紫杉醇较单药改善无进展生存期(HR 0.66,P=.038)。
- 间歇组缓解持续时间改善(HR 0.36,P=.006),客观缓解率各组相似。
- 按Hochberg逐步多重性校正,主要终点未达统计学显著(P<.025)。
核心结论
- 间歇瑞拉可利安联合白蛋白结合型紫杉醇较白蛋白结合型紫杉醇单药改善无进展生存期、缓解持续时间和总生存期。
- 基于方案预设的Hochberg逐步多重性校正,主要终点未达统计学显著(P<.025)。
- 该方案的III期评估正在进行中(ClinicalTrials.gov标识符:NCT05257408)。
研究设计与样本
- 三臂、随机、对照、开放标签II期研究(ClinicalTrials.gov标识符:NCT03776812)。
- 纳入既往接受≤4线化疗的复发性、铂耐药/难治性高级别浆液性或子宫内膜样上皮性卵巢癌、原发性腹膜癌、输卵管癌或卵巢癌肉瘤女性患者。
- 患者按1:1:1随机分配至三组。
- 共178例女性被随机分配。
- 主要终点为研究者评估的无进展生存期,客观缓解率、缓解持续时间、总生存期和安全性为次要终点。
主要发现
- 间歇瑞拉可利安联合白蛋白结合型紫杉醇组较白蛋白结合型紫杉醇单药组改善无进展生存期(HR 0.66;log-rank检验P=.038;中位随访11.1个月)。
- 间歇组较单药组改善缓解持续时间(HR 0.36;P=.006)。
- 客观缓解率在各组间相似。
- 在预设的总生存期分析中(中位随访22.5个月),间歇组较白蛋白结合型紫杉醇单药组的总生存期HR为0.67(P=.066)。
- 持续瑞拉可利安联合白蛋白结合型紫杉醇组中位无进展生存期数值上改善,但未较白蛋白结合型紫杉醇单药组带来显著改善。
关键数值与推荐
- 间歇瑞拉可利安联合白蛋白结合型紫杉醇:白蛋白结合型紫杉醇80 mg/m2,瑞拉可利安150 mg于白蛋白结合型紫杉醇给药前一天、当天和给药后一天服用。
- 持续瑞拉可利安联合白蛋白结合型紫杉醇:白蛋白结合型紫杉醇80 mg/m2,瑞拉可利安100 mg每日一次。
- 白蛋白结合型紫杉醇单药:100 mg/m2。
- 白蛋白结合型紫杉醇于每个28天周期的第1、8、15天给药。
- 主要终点未达统计学显著(P<.025)。
临床怎么用
- 作者报告间歇瑞拉可利安联合白蛋白结合型紫杉醇较白蛋白结合型紫杉醇单药改善无进展生存期、缓解持续时间和总生存期,主要终点按Hochberg逐步多重性校正未达统计学显著(P<.025)。
- 作者指出该方案的III期评估正在进行中(ClinicalTrials.gov标识符:NCT05257408)。
局限性
- 基于方案预设的Hochberg逐步多重性校正,主要终点未达统计学显著(P<.025)。
- 持续瑞拉可利安联合白蛋白结合型紫杉醇组中位无进展生存期数值上改善,但未较白蛋白结合型紫杉醇单药组带来显著改善。
- 预设的总生存期分析中间歇组较单药组的总生存期HR为0.67(P=.066)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite therapeutic advances, outcomes for patients with platinum-resistant/refractory ovarian cancer remain poor. Selective glucocorticoid receptor modulation with relacorilant may restore chemosensitivity and enhance chemotherapy efficacy. METHODS: This three-arm, randomized, controlled, open-label phase II study (ClinicalTrials.gov identifier: NCT03776812) enrolled women with recurrent, platinum-resistant/refractory, high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer, or ovarian carcinosarcoma treated with ≤4 prior chemotherapeutic regimens. Patients were randomly assigned 1:1:1 to (1) nab-paclitaxel (80 mg/m2) + intermittent relacorilant (150 mg the day before, of, and after nab-paclitaxel); (2) nab-paclitaxel (80 mg/m2) + continuous relacorilant (100 mg once daily); or (3) nab-paclitaxel monotherapy (100 mg/m2). Nab-paclitaxel was administered on days 1, 8, and 15 of each 28-day cycle. The primary end point was progression-free survival (PFS) by investigator assessment; objective response rate (ORR), duration of response (DOR), overall survival (OS), and safety were secondary end points. RESULTS: A total of 178 women were randomly assigned. Intermittent relacorilant + nab-paclitaxel improved PFS (hazard ratio [HR], 0.66; log-rank test P = .038; median follow-up, 11.1 months) and DOR (HR, 0.36; P = .006) versus nab-paclitaxel monotherapy, while ORR was similar across arms. At the preplanned OS analysis (median follow-up, 22.5 months), the OS HR was 0.67 (P = .066) for the intermittent arm versus nab-paclitaxel monotherapy. Continuous relacorilant + nab-paclitaxel showed numerically improved median PFS but did not result in significant improvement over nab-paclitaxel monotherapy. Adverse events were comparable across study arms, with neutropenia, anemia, peripheral neuropathy, and fatigue/asthenia being the most common grade ≥3 adverse events. CONCLUSION: Intermittent relacorilant + nab-paclitaxel improved PFS, DOR, and OS compared with nab-paclitaxel monotherapy. On the basis of protocol-prespecified Hochberg step-up multiplicity adjustment, the primary end point did not reach statistical significance (P < .025). A phase III evaluation of this regimen is underway (ClinicalTrials.gov identifier: NCT05257408).
引用
- Colombo N, Van Gorp T, Matulonis UA, et al. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J Clin Oncol. 2023. PMID: 37364223. doi:10.1200/JCO.22.02624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。